Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.
Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.Taken together, the results of the present study indicate that HUHS1015 could be developed as an effective anticancer drug for treatment of malignant pleural mesothelioma.
Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.Show MeSH
Related in: MedlinePlus
Mentions: In the cell cycle analysis by flow cytometry, HUHS1015 increases the proportion of sub-G1 phase NCI-H2052 and MSTO-211H cells (Fig. 3a,c), indicating that HUHS1015 induces apoptosis of these cell lines. HUHS1015 (10 μM) increased the proportion of the G1 and S phases of cell cycling and decreased that of the G2/M phase in NCI-H2052 cells (Fig. 3a). The drug also decreased the proportion of the G1 phase without affecting that of the S and G2/M phases in MSTO-211H cells (Fig. 3c). This suggests no common effect of HUHS1015 on cell cycling among malignant pleural mesothelioma cells.
Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.